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ABSTRACT
Gene expression depends on binding of transcrip-
tional regulators to gene promoters, a process
controlled by signalling pathways. The transcrip-
tional repressor B-cell lymphoma (BCL)-6
downregulates genes involved in cell-cycle progres-
sion and becomes inactivated following phosphor-
ylation by the Rac1 GTPase-activated protein kinase
PAK1. Interestingly, the DNA motifs recognized by
BCL-6 and signal transducers and activators of tran-
scription 5 (STAT5) are similar. Because STAT5
stimulation in epithelial cells can also be triggered
by Rac1 signalling, we asked whether both factors
have opposing roles in transcriptional regulation
and whether Rac1 signalling may coordinate a tran-
scription factor switch. We used chromatin
immunoprecipitation to show that active Rac1
promotes release of the repressor BCL-6 while
increasing binding of STAT5A to a BCL-6-regulated
reporter gene. We further show in colorectal cell
lines that the endogenous activation status of the
Rac1/PAK1 pathway correlated with the phosphor-
ylation status of BCL-6 and STAT5A. Three cellular
genes (cyclin D2, p15INK4B, small ubiquitin-like
modifier 1) were identified to be inversely regulated
by BCL-6 and STAT5A and responded to Rac1
signalling with increased expression and corres-
ponding changes in promoter occupancy.
Together, our data show that Rac1 signalling
controls a group of target genes that are repressed
by BCL-6 and activated by STAT5A, providing novel
insights into the modulation of gene transcription by
GTPase signalling.
INTRODUCTION
A crucial process in gene expression is the initiation of gene
transcription. Before ribonucleic acid (RNA) polymerase
II can transcribe the coding information of a given gene
into RNA, it generally needs to be recruited to the respect-
ive gene promoter by speciﬁc transcription factors. These
factors recognize conserved short DNA sequence motifs in
the promoter but usually only bind to them following tran-
scription factor activation and chromatin remodelling.
Consequently, transcriptional regulation is frequently
preceded by cellular signalling events. For example, activa-
tion of growth factor receptors at the plasma membrane
stimulates the Ras/Raf/extracellular signal-regulated
kinase (ERK) pathway, and activated ERK translocates
into the nucleus where it phosphorylates transcription
factors such as Elk-1 and Myc, enabling them to
bind and activate target gene promoters (1). A different
strategy is used by activated cytokine receptors, which
stimulate tyrosine phosphorylation of the signal trans-
ducers and activators of transcription (STAT) family of
transcription factors at the plasma membrane and these
activated factors then translocate into the nucleus to
activate their target genes (2).
Another signalling molecule activated downstream of
membrane receptors is the small guanosine triphosphate
(GTPase) Rac1, initially discovered for its ability to stimu-
late the polymerization of actin ﬁlaments and cell migra-
tion (3). In addition, Rac1 has distinct roles in the
regulation of gene transcription (4). For instance, the
stimulation of c-Jun N-terminal kinase by Rac signalling
leads to the phosphorylation and subsequent activation of
the transcription factors c-jun, activating transcription
factor (ATF), ETS-like transcription factor (ELK) or
activator protein 1 (AP1). A further transcription factor
stimulated by Rac1 signalling is Nuclear factor kappa-
light-chain-gene-enhancer of activated B cells (NF-kB)
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and involves the phosphorylation and proteolytic degrad-
ation of the cytoplasmic inhibitor proteins IkBa and
NF-kB2/p100 (5,6).
Some STAT factors were also reported to be regulated
by Rac1. They form a family of seven transcription
factors, are found in the cytoplasm under basal conditions
and enter the nucleus following their activation by
tyrosine phosphorylation (2). STAT3 binds directly to
active Rac1, possibly targeting STAT3 to tyrosine kinase
signalling complexes (7). In addition, Rac1 and a
GTPase-activating protein, MgcRacGAP, bind directly
to phosphorylated STAT3 and STAT5A, promoting
their nuclear translocation and activity (8,9).
Previously, we reported a novel link between Rac1
signalling and transcriptional regulation. Rac1 activation
leads to p21-activated kinase (PAK1)-mediated phosphor-
ylation of the transcriptional repressor B-cell lymphoma
(BCL)-6 in colorectal tumour cells and inactivates its re-
pressor function (10). BCL-6 was initially identiﬁed as a
repressor gene translocated in B cell non-Hodgkin’s
lymphomas (11–13). Later, BCL-6 expression has also
been detected in non-haematopoietic tissues, including
skeletal muscle (14), uroepithelial cells (15,16), olfactory
sensory neurons (17), skin (18), epithelial cells of the
mammary gland (19) and HeLa cells (20). BCL-6
contains carboxy-terminal zinc ﬁnger modules that bind
DNA in a sequence-speciﬁc manner (21,22). The genes
repressed by BCL-6 are best studied in germinal centre
B cells and involved in lymphocyte activation and
terminal differentiation, including cell-cycle regulation
(12,23–25).
Interestingly, the DNA motifs recognized by BCL-6 are
highly homologous to the core binding sequence
TTCNNNGAA of STAT factors STAT5 (2,26). This
raised the hypothesis that both factors may have
opposing roles in the transcriptional regulation of some
target genes. Here, we used chromatin immunopre-
cipitation (ChIP) to show that active Rac1 promotes
release of the repressor BCL-6 from promoters together
with increased binding of STAT5A. We also identify three
endogenous target genes involved in cell-cycle control that
were inversely regulated by BCL-6 and STAT5A and re-
sponded to Rac1 signalling with a transcription factor
switch.
MATERIALS AND METHODS
Cell culture and transfection
DLD-1 and SW480 colorectal cells were maintained in
Dulbecco’s minimal essential medium and HT29 cells
were kept in Roswell Park Memorial Institute medium
(RPMI) medium, both supplemented with 10% (v/v)
foetal bovine serum (all from Invitrogen) and regularly
checked for absence of mycoplasm infection. Cells were
transfected as previously described (10), using a 1:2
proportion (mg/ml) of DNA:LipofectAMINE 2000
(Invitrogen) and total amounts of transfected plasmid
DNA of 12 mg per 100-mm dish for ChIP assays and
2 mg per 35-mm dish for cell fractionation, reporter assays
and transcript expression analysis in case of DLD-1 and
SW480 cells, but twice the amount for HT29 cells.
Optimal transfection efﬁciencies were 60–80% in DLD-1
or SW480 cells and 40–60% in HT29, as judged micro-
scopically by expression of green ﬂuorescent protein
(GFP)-tagged vector and cells analysed 16–20 h later.
For RNA interference experiments, cells were trans-
fected at 20–40% conﬂuence in 35-mm dishes with either
200 pmol (DLD-1) or 400 pmol (HT29) of the indicated
siRNAs using LipofectAMINE 2000 and analysed 48 h
later. The siRNA oligos against BCL-6 (sc29791),
STAT5A (sc-29495) and PAK1 (sc-29700) were from
Santa Cruz Biotechnology and a scramble control oligo
(50-AGG UAG UGU AAU CGC CUU GTT) from
Euroﬁns MWG Operon.
DNA plasmids and constructs
The following published constructs were received as gifts:
PAK1-wt, kinase-dead dominant negative PAK1-K299R
and constitutively active PAK1-T423E mutants from J.
Chernoff (Philadelphia), and the 5xBCL-6-vector (22)
from V.J. Bardwell (Minnesota). Myc-Rac1, GFP-Rac1
and pEGFP-BCL-6 constructs were previously described
(6,10,27). STrEP-tagged BCL-6 was generated by
subcloning a BamHI/Xho I fragment from pcDNA3-
BCL-6 into vector pEXPR-IBA105 (IBA, Go¨ttingen,
Germany). pEGFP-STAT5A was generated by polymer-
ase chain reaction (PCR) ampliﬁcation of the STAT5A
cDNA from pMX-STAT5A (gift from B. Groner,
Frankfurt) using a forward primer (50-ATG GCG GGC
TGG ATT CAG G) and a reverse primer (50-ATC TCA
GGA CAG GGA GCT TCT) and subcloned into
pEGFPc2 using EcoRI restriction sites. All constructs
were conﬁrmed by automated DNA sequencing.
Analysis of transcript expression by quantitative
reverse transcriptase-PCR
Total RNA was extracted from cell lysates with the
NucleoSpin RNA kit (Macherey–Nagel) and 1 mg reverse
transcribed using random primers (Invitrogen) and
Ready-to-Go You-Prime First-Strand Beads (GE
Healthcare). CCND2, CDKN2B and small ubiquitin-like
modiﬁer 1 (SUMO1) transcript levels were determined by
quantitative PCR (qPCR) on an ABI Prism 7000 Sequence
Detection System (Applied Biosystems) using the primers
and PCR conditions summarized in Supplementary Table
S1. Each cDNA sample was diluted 5-fold to guarantee
accurate pipetting and 5 ml added to each real-time
reaction together with 200 nM primers and SYBR Green
Master Mix (Applied Biosystems). Data were analyzed
with the 7000 SDS 1.1 RQ Software (CT method,
Applied Biosystems) (28) using mock transfections as ref-
erence samples. For comparison of gene expression
between cell lines a pool of cDNAs mixed at equal parts
from the three cell lines was used as reference.
Semi-quantitative reverse transcriptase-PCR was used
to estimate siRNA-mediated knockdown of BCL-6 and
STAT5A expression. RNA polymerase II (as earlier)
was ampliﬁed as a control gene and two serial dilutions
of scramble siRNA sample served to assure semi-qPCR
conditions and estimate knockdown efﬁciency.
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PCR array analysis
The Human Cell-Cycle PCR array (PAHS-020,
SABiosciences/Qiagen) was used according to manufac-
turer’s instructions. An RNA pool from three independent
siRNA experiments performed in DLD-1 or HT29 cells
was reverse transcribed, then added to a SYBR Green/
Rox qPCR Master Mix (PA-012, Qiagen), distributed
into the 96-well array plate and measured by qPCR as
described previously. The quantitative analysis was done
on an ABI Prism 7000 Sequence Detection System
(Applied Biosystems) with the following cycling condi-
tions: 10 min at 95C and 40 cycles at 95C for 15 s and
60C for 60 s. Two PCR arrays were used for each experi-
mental condition. Data analysis was performed using the
Excel-based tool provided by the manufacturer.
Identiﬁcation of putative BCL-6/STAT5 binding sites
A 2500 bp of the genomic sequence immediately upstream
the annotated transcription initiation sites for CCND2,
CDKN2B and SUMO1 genes were used to search
in silico for putative binding sites recognized simultan-
eously by BCL-6 and STAT5A. Several algorithms were
employed (http://www.gene-regulation.com/; http://www
.biobase-international.com/; http://www.genomatix.de)
using the score values obtained for the previously
described BCL-6/STAT5 site in CCND2 (29) as a refer-
ence for parameter adjustment and best putative site
selection.
Chromatin immunoprecipitation
When indicated, DLD-1, SW480 or HT29 cells were trans-
fected with expression vectors and assayed 16 h later.
ChIP was performed as previously described (29).
Brieﬂy, approximately 10 x 106 cells per ChIP were
cross-linked with 1% formaldehyde, lysed and sonicated
to produce chromatin fragment between 200 and 500 bp
(40% power on a Sonics Vibra Cell sonicator). Cleared
samples were incubated overnight at 4C with either
anti-BCL-6 N3 (Santa Cruz Biotechnologies),
anti-STAT5A (Invitrogen) or control anti-rabbit immuno-
globulin G (DakoCytomation; P 0448) antibodies,
preserving 1/10 lysate volume as input control. Protein
G-conjugated magnetic beads (Invitrogen) were then
added for 1 h at 4C. Beads were thoroughly washed
and co-precipitated DNA was puriﬁed with the
QIAquick PCR puriﬁcation kit (Qiagen) after cross-link
reversion. The selected putative STAT5A/BCL-6 binding
regions were ampliﬁed from ChIP samples, with the
primers and conditions described in Supplementary
Table S1. As a speciﬁcity control, a genomic fragment
between intron 8 and intron 10 of the MutY homolog
(MUTYH) gene (Accession number NG_008189) was
ampliﬁed. Products were separated on 2% agarose gels
containing ethidium bromide. Two serial dilutions of the
‘‘input DNA’’ control were co-ampliﬁed to guarantee
semi-qPCR conditions and allow product quantity ex-
trapolation from band intensities analysed on digital
images using ImageJ software (National Institutes of
Health), which were then normalized to the control
sample.
SDS-PAGE, Western blotting and Rac pull-down assays
Samples were prepared and detected as described (10). The
antibodies used for Western blots were rabbit polyclonal
anti-c-Myc A14, anti-Histone H2B (sc-10808) and rabbit
anti-BCL-6 (clone N3, sc858) from Santa Cruz
Biotechnology, monoclonal anti-GFP (#11814460001)
from Roche, monoclonal anti-Rac1 (clone 23A8) from
Upstate Biotechnologies (#05-38), anti-PAK1 ab40795
from Abcam, polyclonals anti-phospho-PAK1 (Ser199/
204)/PAK2 (Ser192/197) (#2605) and anti-phospho-
STAT5A (Tyr694) (#9351) from Cell Signalling
Technology, monoclonal anti-STAT5A from Invitrogen
(#13-3600) and monoclonal anti-a-tubulin clone B-5-1-2
(as loading control) from Sigma-Aldrich (T6074). The
Rac pull down assay was as described (6). For densitomet-
ric analysis, ﬁlms from at least three independent experi-
ments were digitalized and analysed using ImageJ
software (National Institutes of Health).
Cell fractionation
Proteins were separated into a soluble pool not retained in
the nucleus and into a chromatin-bound insoluble pool
according to previously described procedures (10,30).
Brieﬂy, cells were washed in cold PBS, scraped off and
lysed on ice in fractionation buffer [50 mM Tris-HCl,
pH 7.9, 0.1% (v/v) NP40, 1.5 mM MgCl2, 10 mM KCl
and a protease inhibitor cocktail (Sigma)]. The soluble
fraction was collected by centrifugation and adding the
supernatant to 5 Laemmli SDS sample buffer. The
pellet containing the insoluble fraction in nuclei was
washed once in fractionation buffer and then resuspended
in 1 Laemmli sample buffer. Equal volumes of both frac-
tions were analysed side by side on Western blots. Results
were conﬁrmed in at least three independent experiments.
Confocal immunoﬂuorescence microscopy
Experiments were performed as described (10) and images
recorded with a Leica TCS-SPE confocal microscope.
Luciferase Reporter Assay
The use of the pGL3-5xBCL-6 reporter vector in DLD-1
cells was previously described (10). Brieﬂy, cells were
co-transfected with pRL-TK luciferase reporter (internal
control; Promega), pGL3-5xBCL-6 or pGL3 control
reporters, and the indicated expression constructs. After
16–20 h cells were lysed and assayed with the Dual
Luciferase Reporter Assay (Promega) and measured in
an Anthos Lucy-2 Luminometer. Lysates were assayed
in duplicates and additional aliquots analysed by
Western Blot to document protein expression levels.
Normalized luciferase values were plotted as fold-increase
over the value of control treatments and correspond to at
least three independent transfection assays.
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Statistical analysis
Statistical signiﬁcance of the differences between treated
and control samples was analyzed using two-tailed
Student’s t-tests and indicated in the ﬁgures by an
asterisk (*) whenever p< 0.05.
RESULTS
Rac1 signalling promotes transcription by repressing
BCL-6 and stimulating STAT5
Recently, we used a BCL-6 reporter gene construct
(Figure 1A) in which ﬁve repeats of a BCL-6 recognition
motif control luciferase expression and found that Rac1
signalling acts as an upstream regulator of BCL-6 in colo-
rectal DLD-1 cells (10). When this reporter gene was
transfected into DLD-1 cells together with GFP-tagged
BCL-6, a further repression was observed, whereas
depletion of endogenous BCL-6 expression by RNA inter-
ference led to transcriptional activation (Figure 1B). In the
course of these studies, we noticed that the expression of
active Rac1-Q61L had a stronger stimulatory effect on
reporter gene transcription than a constitutively active
PAK1-T423E mutant (Figure 1B), although PAK1 is
activated downstream of Rac1 and was shown to phos-
phorylate BCL-6 (10). We thus reasoned that Rac1 may
activate additional PAK1-independent pathways that
affect reporter gene activation. One candidate pathway
was activation of STAT5 because STAT5 was reported
to recognize BCL-6 binding motifs in some cellular
genes, including cyclin D2 or prolactin (25,29,31–33),
and because it formed a complex with active Rac1
promoting STAT5 nuclear import and transcriptional ac-
tivation (9).
To test whether active Rac1 could promote nuclear
translocation of STAT5 in DLD-1 cells, we ﬁrst applied
Figure 1. Rac1 signalling promotes transcription by repressing BCL-6 and stimulating STAT5. (A) Schematic representation of the transcriptional
luciferase reporter vector under the control of ﬁve consensus BCL-6 binding motifs. (B) DLD-1 cells were co-transfected with the reporter vector and
the indicated expression vectors or siRNAs. Cells were lysed 24 h later and luciferase activity was measured and graphically displayed, *P< 0.05. The
Western blot below the graph shows the levels of transfected GFP-tagged BCL-6, Rac1-L61, PAK1 kinase dead (kd) or PAK1 constitutively active
(ca) mutants. Detection of endogenous a-tubulin served as loading control. The small insert beside the graph shows a Western blot of endogenous
BCL-6 to document the efﬁciency of its siRNA-mediated depletion.
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Figure 2. Rac1 signalling switches promoter occupancy from BCL-6 to STAT5. (A) DLD-1 cells were transfected with Myc-Rac1-Q61L or control
empty vector and 24 h later analyzed by Western blot for the subcellular distribution of STAT5 between a soluble (S) and a chromatin-bound
non-soluble (NS) fraction (detection of a-tubulin and histone 2B served as controls). Note that active Rac1 promotes retention of STAT5 in the
non-soluble chromatin fraction. (B) Subcellular localization of STAT5 determined by confocal ﬂuorescence microscopy in DLD-1 cells co-transfected
with DsRed-Rac1-Q61L and GFP-STAT5A. The overlay image of the DAPI, GFP and DsRed channels is shown. A microscopic ﬁeld was chosen
that contained side by side untransfected cells (blue nuclei), cells that transfected only with GFP-STAT5 (green cells) and cells that co-transfected
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a cell fractionation protocol, which separates transcription
factors into a soluble pool that is extracted from the
nucleus and a chromatin-bound pool that remains insol-
uble (10). Under control conditions, STAT5 was detected
in the soluble fraction (Figure 2A), whereas in cells
co-expressing an active Rac1-Q61L mutant a notable tran-
sition of STAT5 into the chromatin-bound insoluble
fraction was observed (Figure 2A). Second, we visualized
the effect of active Rac1 on STAT5 by ﬂuorescence mi-
croscopy in cells co-transfected with DsRed-Rac1-Q61L
and GFP-STAT5A. As shown in Figure 2B, a clear tran-
sition of STAT5 into the nucleus was observed.
To conﬁrm whether STAT5 was able to activate the
BCL-6 reporter gene under these conditions, both con-
structs were co-transfected into DLD-1 cells and increased
luciferase transcription was measured (Figure 2C). We
then co-expressed STAT5 and constitutively active
PAK1 to test whether their combined transcriptional ac-
tivation would mimic that induced by Rac1-Q61L. As
shown in Figure 2C, simultaneous stimulation of PAK1
and STAT5 could indeed account for the complete stimu-
latory effect induced by Rac1 signalling.
Rac1 signalling switches promoter occupancy from
BCL-6 to STAT5
These results suggested that Rac1 signalling activates two
independent pathways of transcriptional regulation that
target the same reporter gene. To obtain further support
for this conclusion, we determined the occupancy of the
reporter gene promoter by either BCL-6 or STAT5 under
the various experimental conditions. For this, DLD-1 cells
were co-transfected with the BCL-6 reporter gene and
either control vector or active Rac1-Q61L or active
PAK1-T423E and the presence of either transcription
factor at the reporter gene promoter was analysed by
ChIP. As shown in Figure 2D, BCL-6 was the predomin-
antly bound factor in control cells, however, upon expres-
sion of active Rac1 BCL-6 binding was reduced and
STAT5 became the predominantly bound factor at the
promoter. To exclude that the observed changes in
promoter occupancy were the result of epitope masking
(due to an interaction of BCL-6 and STAT5 at the
promoter that could interfere with recognition by their
speciﬁc ChIP antibodies), co-precipitation studies were
carried out (Supplementary Figure S1). No evidence was
found for complex formation between the two transcrip-
tion factors, indicating that changes in promoter occu-
pancy reﬂected changes in bound proteins. In case of
active PAK1, BCL-6 was also partially reduced, and this
is in agreement with our previous data that PAK1 phos-
phorylates BCL-6 and promotes its release from chroma-
tin and loss of repressor activity. However, in contrast to
active Rac1, PAK1 was unable to invert the promoter
occupancy from BCL-6 to STAT5. Together, these data
support the conclusion that Rac1 signalling activates two
independent pathways to promote a switch in promoter
occupancy from BCL-6 to STAT5.
Correlation of Rac1 signalling and activation of BCL-6 or
STAT5 in different cell lines
To understand the physiological relevance of the observed
transcriptional switching at the reporter gene, we ﬁrst
characterized the endogenous activity levels of Rac1,
PAK1, STAT5 and BCL-6 in three different colorectal
cell lines using Western blot analysis. As shown in
Figure 3, SW480 cells revealed the strongest endogenous
Rac1 activation level, followed by HT29 and DLD-1 cells.
Curiously, SW480 cell lost PAK1 expression, whereas in
HT29 and DLD-1 cells, active Rac1 was proportional to
active PAK1, as well as to the levels of phospho-BCL-6
Figure 2. Continued
with both GFP-STAT5 and DsRed-Rac1-Q61L (red cells). Note the nuclear STAT5 signal in Rac1-expressing red cells. In addition, two plots are
given showing the DAPI and GFP signal intensities measured along the indicated regions of interest (ROI, white lines). The signal intensity of GFP
did not increase across the nuclear DAPI region when cells expressed only GFP-STAT5 (green cells, ROI 1), whereas nuclear GFP signal clearly
increased when cells co-expressed active Rac1 (red cells, ROI 2), conﬁrming nuclear translocation of GFP-STAT5. (C) DLD-1 cells were
co-transfected with the reporter and the indicated expression vectors, as described for Figure 1B. Note that STAT5 activates the BCL-6 luciferase
reporter and, when combined with PAK1, reaches the stimulation levels normally induced by active Rac1, *P< 0.05 and #P> 0.05. (D) Chromatin
immunoprecipitation (ChIP) of the reporter vector with anti-(a)-BCL-6, a-STAT5 or a non-speciﬁc antibody (NS immunoglobulin G) from lysates of
DLD-1 cells transfected with the indicated expression vectors. A representative semi-qPCR of the precipitated promoter fragment quantities with a
graphical representation of the respective band intensities quantiﬁed by densitometry from digital images obtained in 3 independent transfection
experiments, *P< 0.05, is shown. Two serial dilutions of input DNA were co-ampliﬁed to guarantee semi-qPCR conditions and allow product
quantity extrapolation from band intensities.
Figure 3. Correlation of Rac1 signalling and activation of PAK1,
BCL-6 or STAT5 in different cell lines. Equivalent lysate quantities
of DLD-1, SW480 and HT29 colorectal cells were separated by gel
electrophoresis and analysed by Western blot using the indicated
antibodies to compare protein levels. The active Rac1 fraction was
obtained by CRIB-pull down assays, as described (6).
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and phospho-STAT5. Interestingly, SW480 cells
expressed BCL-6 as well as STAT5 but lacked any sig-
niﬁcant activation by phosphorylation. This suggested
that repression by BCL-6 should be predominant in
these cells, indicating their usefulness as a negative
control for the transcriptional switch to STAT5 in subse-
quent experiments.
Identiﬁcation of endogenous genes inversely regulated by
BCL-6 and STAT5
As a next step to identify physiological targets of
the observed transcriptional switching, an array of 84
cell-cycle-related genes was tested for opposite effects of
BCL-6 and STAT5 on gene expression. For this, the
two cell lines that showed endogenous BCL-6 and
STAT5 activation, DLD-1 and HT29, were inde-
pendently transfected with small interfering RNAs tar-
geting either BCL-6 or STAT5 (Supplementary
Figure S2). qPCR analysis of the resulting gene expres-
sion levels identiﬁed three genes that were affected in
opposite sense by the downregulation of either BCL-6 or
STAT5, namely cyclin D2 (CCND2), cyclin-dependent
kinase inhibitor p15INK4B (CDKN2B), and SUMO1
(Figure 4A).
To determine the respective promoter occupancies in
these three genes, overlapping binding motifs for BCL-6
and STAT5 were identiﬁed using a Transfac database-
based algorithm (see Methods section and Figure 4B) and
used to design ChIP experiments in the three aforemen-
tioned cell lines. It was found that both factors were
bound to the 3 identiﬁed promoters regions, albeit to dif-
ferent extent; however, not to a control genomic fragment.
In SW480 cells (that express no PAK1 and have little
phospho-BCL-6; Figure 3), the predominant factor that
was bound to all 3 promoters was BCL-6, whereas
STAT5 was close to background levels (Figure 5A, grey
bars). In contrast, HT29 cells contained more STAT5
bound to these promoters than BCL-6 (Figure 5A, white
bars), in agreement with their higher endogenous levels
of active PAK1, phospho-BCL-6 and phospho-STAT5
(cf. Figure 3). In DLD-1 cells (Figure 5A, black bars),
comparable promoter binding levels were detected for
both factors (except for the cyclin D2 promoter that had
more BCL-6 bound). Again, this is in good agreement
with the observation described in Figure 3 that endogen-
ous levels of active PAK1, phospho-BCL-6 and phospho-
STAT5 in DLD-1 were lower than in HT29 but higher
than in SW480 cells (Figure 3).
Next, these data on the promoter occupancies of the
CCND2, CDKN2B and SUMO1 genes were matched to
the corresponding gene expression levels, validated by
qPCR using independently designed PCR primers
(Figure 5B). HT29 cells that had less BCL-6 repressor
bound than DLD-1 cells also revealed higher expression
levels for all three genes. Surprisingly, SW480 cells also
expressed all three genes considerably, although BCL-6
was predominantly bound in these cells, indicating they
use different mechanisms to activate these cell-cycle
regulating genes.
Rac1 signalling controls reciprocal roles of BCL-6 and
STAT5 in target gene expression
As ﬁnal evidence that the transcription factor switch is
physiologically meaningful, the promoter occupancies at
Figure 4. Identiﬁcation of endogenous genes inversely regulated by
BCL-6 and STAT5. (A) DLD-1 and HT29 cells were transfected with
either BCL-6 or STAT5-speciﬁc siRNA oligonucleotides and lysed fol-
lowing 48 h for RNA extraction. (Supplementary Figure S2). A heat
map display of the gene expression analysis of a cell-cycle PCR array
probed with RNA samples obtained from BCL-6 or STAT5-depleted
DLD-1 and HT29 cells, is shown. Of the 84 genes on the array, 3 were
identiﬁed to be regulated by BCL-6 and STAT5 in opposite sense
(white boxes). (B) Schematic representation of the promoter regions
of the three endogenous genes inversely regulated by BCL-6 and
STAT5 showing the selected best putative motifs, with equivalent pre-
dicted binding scores for both factors.
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the 3 genes were determined and compared with changes
in their respective expression levels following activation or
inhibition of Rac1 signalling in the 3 different cell lines.
For this, cells were transfected with vectors encoding
either PAK1, or dominant negative or active Rac1, or
with siRNA oligonucleotides directed against endogenous
PAK1 (depletion documented in Figure S2B). The 3 genes
revealed equivalent results, which are represented in
Figure 6 for the SUMO1 gene by displaying the levels of
promoter-bound BCL-6 or STAT5 alongside the respective
target gene transcript levels. Comparable data for the
CCND2 and CDKN2B genes are shown in Figures S3
and S4, respectively. When PAK1 was transfected into
SW480 cells, which lack endogenous PAK1, a loss of
BCL-6 from the promoter of all three genes was induced,
which slightly increased their expression levels. By contrast,
the depletion of endogenous PAK1 had no effect on
promoter occupancy or gene expression (Figure 6 middle
panel), a result in agreement with the fact that no endogen-
ous PAK1 is expressed in SW480 cells. When SW480 cells
Figure 5. Regulation of expression of the CCND2, CDKN2B and SUMO1 genes. (A) Promoter occupancies with BCL-6 and STAT5 at the
CCND2, CDKN2B and SUMO1 gene promoters was determined by ChIP with the indicated antibodies using lysates of the three indicated cell
lines (see legend to Figure 2D for details). A representative semi-qPCR of the precipitated promoter fragments and a graphical representation of the
respective band intensities, *P< 0.05, are shown. A control genomic fragment from the MUTYH gene was ampliﬁed to conﬁrm the speciﬁcity of the
precipitated target gene promoters. Note that BCL-6 binds predominantly in the PAK1-lacking SW480 cells and whereas a switch to STAT5 occurs
in HT29 cells with active Rac1/PAK1 signalling. (B) Gene expression data corresponding to the ChIP analysis of the three genes in the three cell
lines. Left panel shows representative semi-quantitative reverse transcriptase-PCRs (RT-PCRs), whereas graph at the right shows the result of qPCR
analysis of cDNAs collected from the three cell lines at three different splitting times. Genes encoding RNA polymerase II (pol 2) and the glycolytic
enzyme phosphoglycerate kinase (PGK1) were ampliﬁed as control housekeeping genes and a pool of cDNAs mixed at equal parts from the three cell
lines was used as reference for qPCR. Serial dilutions served to assure semi-quantitative conditions in the conventional RT-PCR reactions.
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were transfected with active Rac1, a small increase in
STAT5 phosphorylation and binding to the promoter
was observed; however, the overall effect on gene expres-
sion was negligible because the lack of PAK1 compromised
BCL-6 removal from the promoter. These data conﬁrm our
previous assumption that SW480 cells represent a negative
control and cannot respond to Rac1 signalling with the
transcriptional switch between BCL-6 and STAT5.
In contrast, HT29 and DLD-1 cells both switched
BCL-6 and STAT5 at the three gene promoters upon
transfection with active Rac1, accompanied by a clear
increase in STAT5 phosphorylation and in gene expres-
sion. Upon transfection of these cells with PAK1, BCL-6
was lost from the three gene promoters and expression
increased slightly; however, no signiﬁcant increase in
STAT5 phosphorylation occurred. In the presence of
PAK1-speciﬁc siRNAs (as well as a dominant negative
PAK1 mutant), BCL-6 promoter occupancy increased
and expression of the three genes was inhibited.
Altogether, these data provide evidence for the model
proposed in Figure 7, showing that Rac1 signalling has a
dual effect on transcriptional regulation of the CCND2,
CDKN2B and SUMO1 genes. First, Rac1 activates PAK1
which phosphorylates BCL-6 leading to its removal from
the target gene promoter and a concomitant increase
in gene expression. In parallel, Rac1 activates phos-
phorylation and nuclear translocation of STAT5, which
binds to the same sequence motif in the gene promoter
that is recognized by BCL-6 and further increases gene
expression.
DISCUSSION
The main ﬁnding in this work is that Rac1 signalling
activates gene transcription by inducing a switch from re-
pressor BCL-6 to activator STAT5 at the promoter of
certain cellular target genes in colorectal cells.
Although BCL-6 is best known as a regulator of B
lymphocyte growth and differentiation, it is also expressed
in epithelial tissues including skin (18), the mammary
gland (19), HeLa cells (20) and colorectal cells (10).
Similarly, STATs were described as integral parts of
cytokine signalling pathways in haematopoietic cells (2),
but meanwhile their role in epithelial cancers has been well
Figure 6. Rac1 signalling controls target gene expression by inverting promoter occupancy with either BCL-6 or STAT5. The representative analysis
of the SUMO1 gene is shown in the indicated three colorectal cell lines following their transfection with constructs that either activate or inhibit Rac1
signalling. Top panels show the graphical display of promoter occupancy by ChIP using either anti-BCL-6 (black columns) or STAT5 (white
columns) and middle panels the respective gene expression levels (grey columns) (see legend to Figure 5 for further details), *P< 0.05. Bottom
panels show Western blot analysis of the cell lysates demonstrating the expression levels of the transfected GFP, GFP-Rac1 or GFP-PAK1 con-
structs as well as the resulting phosphorylation status of endogenous STAT5. Note that in SW480, which lack endogenous PAK1, depletion of
endogenous PAK1 by siRNAs transfection (documented in Fig. S2B) or expression of dominant negative PAK1 has no effect on promoter-bound
BCL-6, whereas re-expression of PAK1 leads to loss of BCL-6 from the SUMO1 promoter and an increase in gene expression. In the other two cell
lines, inhibition of Rac1 or PAK1 are clearly correlated with more BCL-6 bound and less gene expression while activation of Rac1 or PAK1
promoted STAT5 binding to the promoters and increased transcription.
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documented (34). In particular, aberrant activation of
STAT5 was found in prostate (35) and colorectal cancer
(36). In these cases, the activation of STAT5 can be
mediated by Rac1 signalling, either through the produc-
tion of reactive oxygen species downstream of G-protein
coupled receptor stimulation, leading to activation of the
tyrosine kinase JAK (37) and/or through complex forma-
tion with MgcGAP promoting nuclear import of
phospho-STAT5 (9). Indeed, our study in the colorectal
cell lines conﬁrmed that activated Rac1 led to increased
phosphorylation of STAT5 (Figure 6) and an increase in
chromatin-bound nuclear STAT5 (Figure 2A).
Previous reports have suggested that STAT5 and BCL-6
could bind in a mutually exclusive manner to the same
sequence motif in the promoters of certain target genes
(25,29,31–33). Our data clearly support these studies and
show, side-by-side, that the switch in promoter occupancy
between BCL-6 and STAT5 correlates directly with
changes in gene expression of either a BCL-6-controlled
luciferase reporter vector or of three endogenous gene pro-
moters. More importantly, we show for the ﬁrst time that
this switch is regulated by Rac1 signalling and occurs in
colorectal tumour cells. Several pieces of evidence
contributed to these data. First, ChIP assays revealed
that BCL-6 and STAT5 were bound to the identiﬁed
gene promoters in the three colorectal cell lines. Second,
the endogenous activation status of Rac1, PAK1, and
phosphorylated BCL-6 or STAT5 correlated well with
promoter occupancies in the cell lines, without detectable
changes in the total amount of STAT5 or BCL-6 proteins.
Third, experimental activation of Rac1 promoted STAT5
phosphorylation and accumulation in the chromatin-
bound nuclear fraction. Fourth, the transcript expression
levels of the three endogenous genes mirrored their
promoter occupancies and responded to activation or in-
hibition of upstream Rac1 or PAK1 signalling.
As described earlier, the three colorectal cell lines
studied differed in their endogenous activation levels of
Rac1 signalling and the resulting inhibition of BCL-6 or
stimulation of STAT5. SW480 cells apparently lost PAK1
expression and therefore are unable to phosphorylate
BCL-6, except when transfected with ectopic PAK1
(Figure 6). Unexpectedly, these cells still revealed signiﬁ-
cant expression of the CCND2, CDKN2B and SUMO1
genes, which we identiﬁed as inversely regulated target
genes for BCL-6 and STAT5. This experimental observa-
tion indicates that other mechanisms for transcriptional
activation of CCND2, CDKN2B and SUMO1 exist and
were used by these cells. Because the control of gene ex-
pression involves combinatorial patterns of transcription
factor binding, the inhibitory effect of BCL-6 was most
likely overcome in SW480 cells by other transcription
Figure 7. Proposed model for the role of Rac1 signalling in the observed transcriptional switch. On receptor activation, exchange factors (GEF)
promote GTP binding of Rac1 that stimulates two independent pathways. Active Rac1 binds and activates protein kinase PAK1 that migrates into
the nucleus and phosphorylates chromatin-bound BCL-6, leading to its inactivation and loss of promoter occupancy. In parallel, a protein complex is
formed between active Rac1, MgcRacGAP and STAT5, promoting phosphorylation by a tyrosine kinase (TK) and translocation into the nucleus.
Here, MgcRacGAP stimulates GTP hydrolysis by Rac1 and phospho-STAT5 is released and activates gene transcription following binding to the
vacant promoter sites previously repressed by BCL-6.
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factors that respond to different signalling inputs. For
example, the ability of Myc to induced CCDN2 as well
as CDKN2B expression has been reported (38,39) and
SW480 cells carry an oncogenic mutation in the KRAS
gene (28), a strong activator of several signalling
pathways.
In contrast, HT29 and DLD-1 cells shared the same
regulatory pattern of BCL-6 inhibition and STAT5 acti-
vation, differing only in the extent of BCL-6 inhibition,
which was more pronounced in HT29 cells. However, on
transfection of active Rac1 or PAK1 mutants, the result-
ing transcriptional stimulation became almost identical in
both cell lines. The same was true for the strong inhibitory
effect after depletion of endogenous PAK1 by RNA inter-
ference or transfection of a dominant-negative PAK1
mutant, whereas SW480 cells did not respond to either
treatment. Together, these data provide substantial
evidence that Rac1 signalling promotes a switch at the
targeted promoters with a release of BCL-6 and
enhanced binding of STAT5 to the same site.
Of the 84 cell-cycle related genes analysed, 3 (3.6%)
were clearly identiﬁed as inversely regulated by BCL-6
and STAT5. CCND2 encodes cyclin D2, which functions
as a regulatory subunit of CDK4 or CDK6 required for
cell-cycle G1/S transition. CCND2 overexpression has
been reported in colorectal tumours and cell lines (40,41).
The SUMO1 gene encodes a small ubiquitin-like
protein that can be covalently attached to proteins as a
monomer or a lysine-linked polymer. Unlike ubiquitin,
sumoylation is not involved in proteolytic degradation
of the attached protein but rather modulates nuclear
transport or transcriptional regulation (42).
CDKN2B encodes the cyclin-dependent protein kinase
inhibitor protein p15 encoded by the INK4b locus, which
can form a complex with CDK4 or CDK6, and prevent
their activation by cyclin D. Although CCND2 and
SUMO-1 overexpression are consistent with the pro-
proliferative role usually associated with increased Rac1
signalling, the role of CDKN2B during colorectal cancer
progression remains unclear. Intriguingly, the expression
of p15 was also found signiﬁcantly increased in higher
grade prostate carcinomas (43), indicating that alternative
mechanisms may exist to inactivate its inhibitor function.
Although the particular functional consequences
require further clariﬁcation, our ﬁndings provide a mech-
anistic model for how Rac1 signalling promotes switching
between transcription factors (Figure 7). Beyond the rapid
regulation by Rac1 signalling, the described interplay
between STAT5 and BCL-6 is likely also modulated at
the long term because STAT5 was found to act as a tran-
scriptional repressor on the BCL-6 gene itself (44). In
addition, STAT5 has been described to act as a transcrip-
tional repressor on other genes (45,46). This underlines the
requirement for a genome-wide study to understand which
genes are activated or repressed by BCL-6 or STAT5
alone, and which genes are regulated reciprocally by the
switch between both factors that is described in this manu-
script. These differences could reside in the sequence
motifs of the corresponding promoters or be mediated
by the binding of additional protein factors. Our data
are thus a contribution to uncover how Rac1 signalling
shapes gene expression and how the deregulation of Rac1
activity that is observed for example in cancer (47)
promotes cell proliferation.
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